Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MHLW Report Finds No Relations Between Tamiflu Use And Abnormal Behavior

This article was originally published in PharmAsia News

Executive Summary

A safety team at Japan's Ministry of Health, Labor and Welfare reported June 17 that clinical tests found no evidence that taking Chugai Pharmaceutical's flu drug Tamiflu (oseltamivir phosphate) affected electrocardiograms and sleep patterns. The clinical report also stated that there was no evidence showing relation between the administration of Tamiflu and sudden death or abnormal behavior. The team conducted electrocardiograms on 11 healthy males between the ages of 20-51. The team also conducted researches on brain waves of 31 males aged between 20-24 when sleeping and found no abnormality in brain waves after taking Tamiflu. (Click here for more - Japanese language

Latest Headlines
See All
UsernamePublicRestriction

Register

SC068783

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel